Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy

International Braz J Urol

Volumn 37, Issue 2, 2011, Pages 180-185

  Dall'Oglio, Marcos F ^a   Sousa Canavez, Juliana M ^b   Tanno, Fabio Y ^a   Tiseo, Bruno C ^a   Crippa, Alexandre ^c   dos Reis, Sabrina T ^a   Leite, Katia R M ^a   Srougi, Miguel ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Genoa Biotechnology   (Brazil)

^c ICESP   (Brazil)

Author keywords

Dendritic cells; Neoplasm metastasis; Renal cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; SUNITINIB;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DENDRITIC CELL; HUMAN; IMMUNOLOGY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DENDRITIC CELLS; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEPHRECTOMY; PYRROLES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79959291563     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382011000200004     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-49.
2. Murai M, Oya M: Renal cell carcinoma: etiology, incidence and epidemiology. Curr Opin Urol. 2004; 14: 229-33.
3. Lam JS, Leppert JT, Belldegrun AS, Figlin RA: Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol. 2005; 23: 202-12.
4. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al.: Editors. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute. Bethesda, MD, 2007. [Cited nov 2006]. Available at: http://seer.cancer.gov/csr/1975_2004.
5. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol. 2000; 163: 408-17.
6. Rini BI, Campbell SC, Escudier B: Renal cell carcinoma. Lancet. 2009; 373: 1119-32.
7. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature. 1998; 392: 245-52.
8. Kugler A, Stuhler G, Walden P, Zöller G, Zobywalski A, Brossart P, et al.: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med. 2000; 6: 332-6. Retraction in: Kugler A, Stuhler G, Walden P, Zöller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Müller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Müller GA, Ringert RH. Nat Med. 2003; 9: 1221.
9. Dall'Oglio M, Srougi M, Barbuto JA: Complete response of metastatic renal cancer with dendritic cell vaccine. Int Braz J Urol. 2003; 29: 517-9.
10. Barbuto JA, Ensina LF, Neves AR, Bergami-Santos P, Leite KR, Marques R, et al.: Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother. 2004; 53: 1111-8.
11. de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M: EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer. 2009; 45: 765-73.
12. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, et al.: Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood. 2008; 111: 5610-20.
13. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-34. Erratum in: N Engl J Med. 2007; 357: 203.
14. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-24.
15. Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J, et al.: Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer. 2009; 100: 1111-9.
16. Vogelzang NJ: Treatment options in metastatic renal carcinoma: an embarrassment of riches. J Clin Oncol. 2006; 24: 1-3.
17. Heldwein FL, Escudier B, Smyth G, Souto CA, Vallancien G: Metastatic renal cell carcinoma management. Int Braz J Urol. 2009; 35: 256-70.
18. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427-34.
19. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-81.
20. Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC: Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int. 2007; 100: 755-9.
21. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20: 289-96.
22. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al.: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 3584-90.
23. Kusmartsev S, Vieweg J: Enhancing the efficacy of cancer vaccines in urologic oncology: new directions. Nat Rev Urol. 2009; 6: 540-9.